Vinca derivatives

Details Vinca derivatives Vinca derivatives

2007-07-03

2007-07-03

Coleman, Brenda (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C540S478000

Reexamination Certificate

active

11003560

ABSTRACT:
The present invention relates to derivatives of vinca alkaloids. Pharmaceutical compositions containing these compounds as well as processes of preparation and treatment of various conditions are also disclosed.

REFERENCES:
patent: 4307100 (1981-12-01), Langlois et al.
patent: 4347249 (1982-08-01), Potier et al.
patent: 4388305 (1983-06-01), Trouet et al.
patent: 4430269 (1984-02-01), Pearce
patent: 4639456 (1987-01-01), Trouet et al.
patent: 4737586 (1988-04-01), Potier et al.
patent: 4769453 (1988-09-01), Potier et al.
patent: 5047528 (1991-09-01), Kutney et al.
patent: 6127377 (2000-10-01), Duflos et al.
patent: RE37449 (2001-11-01), Kutney et al.
patent: 6365735 (2002-04-01), Rool
patent: 2004/0186286 (2004-09-01), Fukuyama et al.
patent: 2005/0176748 (2005-08-01), Scott et al.
patent: 2458600 (2003-03-01), None
patent: 2003-064084 (2003-03-01), None
patent: 1 426 377 (2004-06-01), None
patent: WO 2005/055943 (2005-06-01), None
Berge et al., “Pharmaceutical Salts,”Journal Pharmaceutical Sciences66(1):1-19 (1997).
Boyd, M.R., “Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval,” Teicher, B. Ed., Humana Press, Totowa, New Jersey, pp. 23-42 (1997).
Fahy, J., “Modifications in the <<upper >> or Velbenamine Part of theVincaAlkaloids Have Major Implications for Tubulin Interacting Activities,”Current Pharmaceutical Design7:1181-1197 (2001).
Lobert et al., “Vinca Alkaloid-Induces Tubulin Spiral Formation Correlates with Cytotoxicity in the Leukemic L1210 Cell Line,”Biochemistry39:12053-12062 (2000).
Ram & Kumari, “Natural Products of Plant Origin as Anticancer Agents,”Drug News Perspect14(8):465-482 (2001).
Skehan et al., “New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening,”Journal of the National Cancer Institute82(13):1107-1112 (1990).
CAS(R) Registry No. 81600-06-8, 1985.
CAS(R) Registry No. 123286-01-1; 123286-00-0, 1991.
CAS(R) Registry No. 67699-41-6; 67699-40-5, 1984.
Anhydrovinblastine,Pioneer,© IMSworld Publications Ltd (2000) (Update Date May 8, 2000).
Vinxaltine; S 12363,Pioneer,© IMSworld Publications Ltd (2000 (Update Date May 22, 1995).
Vinflunine; F 12158; L 0070,Pioneer,© IMSworld Publications Ltd (2000 (Update Date Apr. 19, 1999).
Napavin,Pioneer,© IMSworld Publications Ltd (2000 (Update Date Oct. 25, 1999).
Registry No. 166533-14-8,SciFinder(Feb. 28, 2002).
Registry No. 105801-71-6,SciFinder(Feb. 28, 2002).
Registry No. 105801-70-5,SciFinder(Feb. 28, 2002).
Registry No. 108893-99-8,SciFinder(Feb. 28, 2002).
Registry No. 108893-98-7,SciFinder(Feb. 28, 2002).
Registry No. 218128-76-8,SciFinder(Feb. 28, 2002).
Registry No. 54112-69-5,SciFinder(Feb. 28, 2002).
Registry No. 108893-97-6,SciFinder(Feb. 28, 2002).
Registry No. 108893-96-5,SciFinder(Feb. 28, 2002).
Registry No. 90012-98-9,SciFinder(Feb. 28, 2002).
Registry No. 90012-97-8,SciFinder(Feb. 28, 2002).

Affiliated with

Also associated with

Rating

Vinca derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vinca derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vinca derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3782253